Endothelial cell effects of cytotoxics: balance between desired and unwanted effects

被引：46

作者：

de Vos, FYFL ^{[1
]}

Willemse, PHB ^{[1
]}

de Vries, EGE ^{[1
]}

Gietema, JA ^{[1
]}

机构：

[1] Univ Groningen Hosp, Div Med Oncol, Dept Internal Med, NL-9700 RB Groningen, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2004年 / 30卷 / 06期

关键词：

Accidental angiogenesis; Metronomic" chemotherapy; vascular toxicity; endothelial damage; angiogenesis inhibitors;

D O I：

10.1016/j.ctrv.2004.05.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since Folkman defined angiogenesis more than 25 years ago as the most important process in tumour growth and metastasis, specific anti-angiogenic agents have been developed. One obvious route to block this process was until recently overlooked, however. Tumour endothelial cells are different from normal endothelial cells and may respond differently to conventional cytotoxics. Chemotherapeutic-induced vascular toxicity has been observed in various clinical studies and seems to be based on endothelial cell damage as seen in vitro in human umbilical vein endothelial cells (HUVEC) models with protracted low-dose cytostatic exposure. Translated into the clinical setting, such "metronomically" administered chemotherapy could lead to anti-angiogenesis enhancing anti-tumour efficacy of cytostatic drugs. This paper reviews the desired anti-tumour endothelial activity versus the unwanted general vascular toxicity of cytostatic drugs. Several ways to enhance the anti-tumour activity and to circumvent the unwanted vascular toxicity of these "accidental" anti-angiogenic drugs will be discussed. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：495 / 513

页数：19

共 159 条

[1] Analysis of mural cell recruitment to tumor vessels [J].

Abramsson, A ;

Berlin, Ö ;

Papayan, H ;

Paulin, D ;

Shani, M ;

Betsholtz, C .

CIRCULATION, 2002, 105 (01) :112-117

[2]

ADAMSON IYR, 1976, ENVIRON HEALTH PERSP, V16, P119, DOI 10.2307/3428592

[3]

ALLEGRINI G, 2004, CANCER CHEMOTH PHARM, V27, P101

[4]

ANDERSON NR, 1993, CANCER, V72, P2287, DOI 10.1002/1097-0142(19931001)72:7<2287::AID-CNCR2820720739>3.0.CO

[5]

2-5

[6]

Axel DI, 1997, CIRCULATION, V96, P636

[7] γ-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor [J].

Basaki Y. ;

Chikahisa L. ;

Aoyagi K. ;

Miyadera K. ;

Yonekura K. ;

Hashimoto A. ;

Okabe S. ;

Wierzba K. ;

Yamada Y. .

Angiogenesis, 2001, 4 (3) :163-173

[8] Cardiotoxicity of the antiproliferative compound fluorouracil [J].

Becker, K ;

Erckenbrecht, JF ;

Häussinger, D ;

Frieling, T .

DRUGS, 1999, 57 (04) :475-484

[9] The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication [J].

Behar, A ;

PujadeLauraine, E ;

Maurel, A ;

Brun, MD ;

Lagrue, G ;

DeChauvin, FF ;

OulidAissa, D ;

Hille, D .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) :653-658

[10]

Bello L, 2001, CANCER RES, V61, P7501

← 1 2 3 4 5 6 7 8 9 10 →